Bayer Crop Science shareholders approve ₹60 dividend at 68th AGM
Bayer Crop Science Limited concluded its 68th AGM on August 19, 2026, with shareholders approving a total dividend payout of ₹150 per share (₹90 interim + ₹60 final) for FY26. The meeting saw strong promoter support, with 100% of promoter shares voting in favor of all resolutions. Key governance matters, including the reappointment of Director Jana Marlen Ackermann and approval of related-party transactions with Bayer AG, were also passed unanimously by eligible voters.

*this image is generated using AI for illustrative purposes only.
Bayer Crop Science Limited shareholders approved a final dividend of ₹60 per equity share of face value ₹10 each for the financial year ended March 31, 2026. The payout was confirmed during the company’s 68th Annual General Meeting (AGM) held on August 19, 2026, via video conferencing. This follows an interim dividend of ₹90 per share already paid during the year.
The meeting, chaired by Chairman Pankaj Patel, concluded with all proposed resolutions passing with the requisite majority. Shareholders also approved material related-party transactions with Bayer AG and ratified the remuneration for cost auditors M/s. D. C. Dave & Co.
Voting Participation and Results
The AGM was conducted through Video Conferencing / Other Audio-Visual Means (VC/OAVM). As on the record date of August 12, 2026, the company had 61,683 shareholders. Voting was conducted via remote e-voting (August 16–18, 2026) and e-voting during the AGM.
Promoter and Promoter Group holders, holding 32,102,999 shares, participated fully, casting votes equivalent to 100% of their holdings across all resolutions. Public institutional holders polled approximately 90.59% of their shares, while public non-institutional participation remained low at roughly 0.17%.
| Resolution | Total Votes Polled | Votes in Favor | % in Favor | Status |
|---|---|---|---|---|
| Adoption of Financial Statements | 38,466,383 | 38,462,881 | 99.99% | Passed |
| Dividend Declaration (₹60 Final) | 38,466,857 | 38,463,476 | 99.99% | Passed |
| Reappointment of Director Ackermann | 38,466,837 | 38,148,995 | 99.17% | Passed |
| Related-Party Transactions (Bayer AG) | 6,363,394 | 6,358,375 | 99.92% | Passed |
| Cost Auditor Remuneration | 38,466,837 | 38,462,605 | 99.99% | Passed |
Note: For the related-party transaction resolution, promoter shares were excluded from voting as per regulatory requirements.
Key Resolutions Passed
The following ordinary and special business items were approved by the members:
- Adoption of audited financial statements for FY26 along with Board and Auditor reports.
- Confirmation of interim dividend payment of ₹90 per share and declaration of final dividend of ₹60 per share.
- Reappointment of Ms. Jana Marlen Ackermann (DIN: 10849470) as a Director, retiring by rotation.
- Approval of material related-party transactions with Bayer AG.
- Ratification of remuneration payable to cost auditors M/s. D. C. Dave & Co. for FY27.
Governance and Voting Process
Ms. Bharati Shetty, Company Secretary and Compliance Officer, facilitated the e-voting process, which included remote voting and voting during the meeting. Mr. Bhaskar Upadhyay of M/s. NL Bhatia & Associates served as the scrutinizer to ensure transparency. The combined results of remote and live e-voting were displayed on the company’s website and the BSE platform as per regulatory timelines.
Vice Chairman and Managing Director Simon-Thorsten Wiebusch and Executive Director and CFO Vinit Jindal addressed queries from pre-registered shareholders during the proceedings. The statutory and secretarial audit reports for FY26 were taken as read, containing no qualifications or adverse remarks.
Historical Stock Returns for Bayer Crop Science
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.87% | -1.12% | -4.48% | -15.74% | -26.29% | -29.01% |
How will the total dividend payout of ₹150 per share impact Bayer Crop Science's retained earnings and future capital allocation for R&D or expansion?
What are the specific terms of the approved related-party transactions with Bayer AG, and how might they influence the subsidiary's operational independence or supply chain dynamics?
Given the extremely low participation rate (0.17%) from public non-institutional shareholders, does this indicate a lack of retail investor interest or potential liquidity concerns for the stock?


































